Given the observed effects of DMTi treatment on tumor cell inflammation and antigen presentation, our work culminated in the evaluation of whether this induction of anti-tumor immunity could potentiate the response to anti-PD-L1 ICI therapy. Here, CD274 is linked to neoplasm.